GlassScriptPhysician profile
John F Dipersio
NPI 1730106295
$48,317.61
in general payments reported to CMS, 2019-2025
19 companies · $6,098 in 2025
The $6,098 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,233 · 2020: $11K · 2021: $15K · 2023: $7,501 · 2024: $304 · 2025: $6,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $1,212 · Food and Beverage: $998 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,172.50 |
| Travel and Lodging | $1,212.38 |
| Food and Beverage | $997.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $25,442.04 | 2019-2023 | |
| Amgen INC. | $6,928.72 | 2019-2021 | |
| Geron Corporation | $3,379.54 | 2025 | Imetelstat |
| Legend Biotech USA INC. | $2,955.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,790.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $2,664.02 | 2025 | |
| Partner Therapeutics, INC. | $2,298.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $1,286.62 | 2023-2024 | |
| Celgene Corporation | $218.70 | 2019-2024 | Onureg |
| Astellas Pharma US INC | $117.49 | 2024 | Xospata |
| Cerus Corporation | $84.80 | 2019-2024 | Intercept Blood System For Platelets |
| Novartis Pharmaceuticals Corporation | $80.25 | 2019-2023 | |
| Pfizer INC. | $54.04 | 2025 | |
| Abbvie INC. | $18.39 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dipersio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.